BioCryst Pharmaceuticals (BCRX) News Today $7.86 +0.03 (+0.38%) Closing price 04:00 PM EasternExtended Trading$7.82 -0.04 (-0.51%) As of 06:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Sold by Segall Bryant & Hamill LLCSegall Bryant & Hamill LLC trimmed its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 4.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,422,196 shares of the biotechnoMarch 28 at 4:50 AM | marketbeat.comHillsdale Investment Management Inc. Increases Stock Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Hillsdale Investment Management Inc. raised its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 65,213.3% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 542,100 shares of the biotechnology company's stockMarch 24, 2025 | marketbeat.comIntech Investment Management LLC Raises Stock Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Intech Investment Management LLC raised its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 80.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 97,793 shares of the biotechnology company'sMarch 24, 2025 | marketbeat.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Up 3.7% - Here's What HappenedBioCryst Pharmaceuticals (NASDAQ:BCRX) Trading 3.7% Higher - Time to Buy?March 22, 2025 | marketbeat.comSemanteon Capital Management LP Purchases 48,184 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Semanteon Capital Management LP grew its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 32.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 197,760 sharesMarch 22, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Has $14.89 Million Stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Charles Schwab Investment Management Inc. boosted its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 4.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,979,992 shMarch 21, 2025 | marketbeat.comNorth Carolina biotech sues to block copies of $400M drugMarch 20, 2025 | bizjournals.comInstitutional investors control 75% of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) and were rewarded last week after stock increased 4.9%March 18, 2025 | uk.finance.yahoo.comConnor Clark & Lunn Investment Management Ltd. Sells 48,460 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Connor Clark & Lunn Investment Management Ltd. trimmed its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 7.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 633,864 shares of the biotecMarch 17, 2025 | marketbeat.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Purchased by Jupiter Asset Management Ltd.Jupiter Asset Management Ltd. increased its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 10.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,177,929 shares of the biotechnoloMarch 14, 2025 | marketbeat.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Recommendation of "Moderate Buy" from BrokeragesBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) has been given an average recommendation of "Moderate Buy" by the seven research firms that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and six have assignedMarch 14, 2025 | marketbeat.comPrincipal Financial Group Inc. Sells 393,607 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Principal Financial Group Inc. reduced its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 95.7% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 17,807 shares of the biotechnMarch 9, 2025 | marketbeat.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Trading Down 4.4% - What's Next?BioCryst Pharmaceuticals (NASDAQ:BCRX) Trading Down 4.4% - What's Next?March 6, 2025 | marketbeat.comBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 6, 2025 | globenewswire.comBioCryst CFO Anthony Doyle to resign, effective April 9March 4, 2025 | markets.businessinsider.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Sold by Fisher Asset Management LLCFisher Asset Management LLC lowered its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 4.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 3,182,617 shares of the biotechnology company's stockMarch 4, 2025 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Krystal Biotech (KRYS) and BioCryst (BCRX)March 3, 2025 | markets.businessinsider.comIeq Capital LLC Takes Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Ieq Capital LLC acquired a new position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 29,436 shares of the biotechnology company's stockMarch 2, 2025 | marketbeat.comIs BioCryst Pharmaceuticals, Inc. (BCRX) the Best Small-Cap Stock to Buy Now?March 1, 2025 | insidermonkey.comResearch Analysts Offer Predictions for BCRX Q1 EarningsBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) - Equities researchers at Wedbush issued their Q1 2025 earnings per share estimates for shares of BioCryst Pharmaceuticals in a research report issued on Tuesday, February 25th. Wedbush analyst L. Chico forecasts that the biotechnology coFebruary 27, 2025 | marketbeat.comBioCryst: Orladeyo's Expansion Is Just Getting StartedFebruary 27, 2025 | seekingalpha.comBioCryst: Hold Steady As Orladeyo Builds, But Competition Heats UpFebruary 26, 2025 | seekingalpha.comEvercore ISI Sticks to Their Buy Rating for BioCryst (BCRX)February 26, 2025 | markets.businessinsider.comAnalysts Are Updating Their BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Estimates After Its Yearly ResultsFebruary 26, 2025 | finance.yahoo.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q4 2024 Earnings Call TranscriptFebruary 26, 2025 | msn.comBioCryst: Upgrading On Strong 2024 Orladeyo Sales, But I Remain SkepticalFebruary 25, 2025 | seekingalpha.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Given Outperform Rating at Royal Bank of CanadaRoyal Bank of Canada restated an "outperform" rating and set a $11.00 price target (up from $10.00) on shares of BioCryst Pharmaceuticals in a research report on Tuesday.February 25, 2025 | marketbeat.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Coverage Initiated at WedbushWedbush began coverage on shares of BioCryst Pharmaceuticals in a report on Tuesday. They set an "outperform" rating and a $15.00 target price on the stock.February 25, 2025 | marketbeat.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Given Buy Rating at HC WainwrightHC Wainwright reiterated a "buy" rating and set a $30.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday.February 25, 2025 | marketbeat.comBioCryst selloff yesterday brings buying opportunity, says JPMorganFebruary 25, 2025 | markets.businessinsider.comBioCryst Pharmaceuticals Inc (BCRX) Reports Strong Q4 and FY 2024 Financial ResultsFebruary 25, 2025 | gurufocus.comBioCryst Pharmaceuticals Inc (BCRX) Q4 2024 Earnings Call Highlights: Strong ORLADEYO Revenue ...February 25, 2025 | gurufocus.comQ4 2024 BioCryst Pharmaceuticals Inc Earnings Call TranscriptFebruary 25, 2025 | gurufocus.comBioCryst reports Q4 EPS (13c), consensus (6c)February 24, 2025 | markets.businessinsider.comBioCryst’s orladeyo shows positive results in angioedema pediatric trialFebruary 24, 2025 | markets.businessinsider.comBioCryst stock drops following Q4 earnings missFebruary 24, 2025 | investing.comBioCryst Pharmaceuticals (BCRX) Q4 2024 Earnings Call TranscriptFebruary 24, 2025 | msn.comWhy BioCryst Pharmaceuticals Stock Tumbled by 10% TodayFebruary 24, 2025 | fool.comBioCryst Pharmaceuticals, Inc. 2024 Q4 - Results - Earnings Call PresentationFebruary 24, 2025 | seekingalpha.comBioCryst Pharmaceuticals Unveils Latest Trial Data, Reports Mixed Q4 EarningsFebruary 24, 2025 | benzinga.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Down on Disappointing EarningsBioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Down on Disappointing EarningsFebruary 24, 2025 | marketbeat.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Posts Quarterly Earnings Results, Misses Expectations By $0.06 EPSBioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) posted its quarterly earnings data on Monday. The biotechnology company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.06).February 24, 2025 | marketbeat.comBioCryst Pharmaceuticals Q4 2024 Earnings: Revenue Surpasses Estimates at $131. ...February 24, 2025 | gurufocus.comBioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key MilestonesFebruary 24, 2025 | globenewswire.comBioCryst Announces Positive Results from APeX-P Trial for ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema Aged 2 toFebruary 24, 2025 | globenewswire.comBioCryst Pharmaceuticals Inc (BCRX) Announces Participation in Upcoming Healthcare ConferencesFebruary 20, 2025 | gurufocus.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Hits New 1-Year High - Should You Buy?BioCryst Pharmaceuticals (NASDAQ:BCRX) Sets New 12-Month High - Here's What HappenedFebruary 19, 2025 | marketbeat.comBioCryst to Present at Upcoming Investor ConferencesFebruary 19, 2025 | globenewswire.comRice Hall James & Associates LLC Sells 82,427 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Rice Hall James & Associates LLC lessened its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 3.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,081,316 shares of thFebruary 18, 2025 | marketbeat.comBioCryst Pharmaceuticals (BCRX) to Release Earnings on MondayBioCryst Pharmaceuticals (NASDAQ:BCRX) will be releasing earnings before the market opens on Monday, February 24, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=664409)February 17, 2025 | marketbeat.com Remove Ads Get BioCryst Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address BCRX Media Mentions By Week BCRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BCRX News Sentiment▼0.970.78▲Average Medical News Sentiment BCRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BCRX Articles This Week▼76▲BCRX Articles Average Week Remove Ads Get BioCryst Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ALKS News Today IONS News Today FOLD News Today LGND News Today DVAX News Today MNKD News Today CLDX News Today NVAX News Today OPK News Today GERN News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BCRX) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioCryst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioCryst Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BCRX Stock Free BCRX Stock Alerts